Volume 17, Number 10—October 2011
CME ACTIVITY
Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009
, Eveline Snelders, Greetje A. Kampinga, Bart J.A. Rijnders, Eva Mattsson, Yvette J. Debets-Ossenkopp, Ed J. Kuijper, Frank H. Van Tiel, Willem J.G. Melchers, Paul E. Verweij, and KuijperTable 2
Characteristics of itraconazole-positive Aspergillus fumigatus isolates, the Netherlands, 2007–2009*
| No. isolates | Mutations in the Cyp51A gene | Median MIC, mg/L (range) | ||
|---|---|---|---|---|
| Itraconazole | Voriconazole | Posaconazole | ||
| 74 | TR/L98H† | >16 (16–>16) | 8 (1–16) | 0.5 (0.25–2) |
| 1 | G54W† | >16 | 0.5 | >16 |
| 1 | P216L† | 16 | 2 | 0.5 |
| 1 | F219I† | >16 | 0.25 | 0.25 |
| 1 | Series‡ | >16 | >16 | 1 |
| 4 | None | >16 (16–>16) | 4 (0.5–4) | 0.2 (0.125–1)
*In vitro susceptibility testing was performed according to the Clinical and Laboratory Standards Institute M38A2 method (32). *In vitro susceptibility testing was performed according to the Clinical and Laboratory Standards Institute M38A2 method (32). |
*In vitro susceptibility testing was performed according to the Clinical and Laboratory Standards Institute M38A2 method (32).
†Mutations that have previously been shown to be associated with azole resistance in A. fumigatus (7,20,21).
‡Series of mutations in Cyp51A-gene: F46Y, G89G, M172V, N248T, D255E, L358L, E427K, and C454C (8).
